At Servier Pharmaceuticals, we are dedicated to bringing the promise of tomorrow to the patients we serve.

We are a commercial stage, privately held United States pharmaceutical company. Launched by Servier Group, a unique global organization operating in more than 150 countries and governed by a non-profit foundation, Servier Pharmaceuticals has the resources and network of an established global pharmaceutical company, while operating with the nimble and entrepreneurial spirit of a biotech. 

As a growing leader in oncology, Servier is committed to finding solutions that will address today's challenges. The company's oncology portfolio of innovative medicines is designed to bring more life-saving treatments to a greater number of patients, across the entire spectrum of disease and in a variety of tumor types. Currently, we have four medicines approved in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML)  and cholangiocarcionoma (CCA). We have also accelerated our investment in hard-to-treat cancers, with more than 50% of research and development dedicated to oncology. Our goal is to serve our patients with the utmost treatment and care to improve the potential for survival.